Hybio Pharmaceutical Asset Resilience Ratio
Hybio Pharmaceutical asset resilience ratio. Hybio Pharmaceutical (300199) has an Asset Resilience Ratio of 0.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300199 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hybio Pharmaceutical (2021–2024)
Asset resilience ratio of Hybio Pharmaceutical from 2021 to 2024. This chart shows how Hybio Pharmaceutical's Asset Resilience Ratio has changed over time. Read total liabilities of Hybio Pharmaceutical for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hybio Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Hybio Pharmaceutical's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.25 Million | 0.04% |
| Total Liquid Assets | CN¥1.25 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: Hybio Pharmaceutical maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hybio Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Hybio Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Hybio Pharmaceutical Asset Resilience Ratio by Year (2021–2024)
Hybio Pharmaceutical asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Hybio Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.04% | CN¥1.11 Million ≈ $161.87K |
CN¥3.01 Billion ≈ $440.20 Million |
-4.41pp |
| 2022-12-31 | 4.45% | CN¥160.57 Million ≈ $23.50 Million |
CN¥3.61 Billion ≈ $528.44 Million |
-7.78pp |
| 2021-12-31 | 12.23% | CN¥477.68 Million ≈ $69.90 Million |
CN¥3.91 Billion ≈ $571.63 Million |
-- |
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more